Antragstellung in Horizon 2020 - Erste Aufrufe in den LifeSciences Morgensternstrasse 24 12207 Berlin www.consultech.de - Dechema
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Antragstellung in
Horizon 2020
Erste Aufrufe in den LifeSciences
Webinar 25.02.2014
Morgensternstrasse 24
12207 Berlin
www.consultech.de
ConsulTech+GmbH+
• Firmen+und+
Beantragung+von+ Forschungseinrichtungen+
Fördermi:eln+
• In+D+(Bund,+Länder)+EU,+USA+
• pharmazeu@sche,+
Spezialisierung+auf+
• Biotechnologische++
LifeSciences+
• medizintechnische+Projekte+
• Iden@fika@on+von+passenden+
Fördermöglichkeiten+
• Zusammenstellung+von+
Consul@ng+ Projektkonsor@en+
• Konzep@on,+Begleitung+der+Projekte+
+von+der+Planungsphase+bis+zum+
Abschlussbericht+
www.consultech.de
ConsulTech+GmbH+
Kleine und
Großunternehmen Mittelständische Forschungseinrichtungen
Unternehmen
www.consultech.de
ConsulTech+GmbH+
Erfolgreiche
EU Projekte seit
Eingeworbene Beratung großer
1994
Fördersumme Forschungsverbünde
Laufende Projekte
(Cluster)
Miracle
Neuroallianz
>250 Mio € EuroCalin
CI3
SmartBees
www.consultech.de
Übersicht+
Förderinstrumente in Beteiligungs- und
Rechtliche Aspekte
Horizon 2020 Förderregeln
Administrative
Aufrufe mit Relevanz Inhaltliche Aspekte
Aspekte im
für die Life Sciences der Antragstellung
Antragsprozess
www.consultech.de
Förderinstrumente in Horizon 2020 Dipl.-Ing. Heidrun Gürtler
Hintergrundinforma@onen+
zu+Horizon+2020+
Vereinfachungen
Laufzeit Budget
vs FP7
• 2014 - 2020 • 80 Mrd. €
Budget'Horizon'2020'in'Mrd'€'
I%Excellent%science%
2,8,%4%% 1,9,%2%% 1,6,%2%%
II%Industrial%leadership%
31,7,%39%% 24,6,%31%%
III%Societal%challenges%
17,9,%22%%
IV%European%Ins@tute%of%Innova@on%and%
Technology%(EIT)%%
V%NonHnuclear%direct%ac@ons%of%the%Joint%
Research%Centre%%
VI%Euratom%
www.consultech.de
Programmstruktur+von+Horizon+2020+
Wissenschaftliche Führende Rolle der Gesellschaftliche
Exzellenz Industrie Herausforderungen
Lösungsansätze
industrie-
wissenschafts- getriebene in 7
getriebene, Forschung Themenfeldern
grundlagen- von
orientierte Unterstützung
übergeordneter
Forschung und Vernetzung
gesellschaftlicher
von KMU
Bedeutung
Gemeinsame Forschungsstelle (JRC)
Europäisches Innovations- und Technologieinstitut (EIT)
EURATOM
www.consultech.de
Programmstruktur+von+Horizon+2020+T+
Bereiche+mit+Relevanz(für(Life(
Science(Unternehmen(
Wissenschaftliche Führende Rolle der Gesellschaftliche
Exzellenz Industrie Herausforderungen
European Research Technologien Gesundheit,
Counsel - ERC • ICT demographischer
Wandel, Wohlergehen
• Nanotechnologie
Future Emerging • Werkstoffe Ernährungssicherheit
Technologies - FET • Biotechnologie (KBBE)
• Produktionstechnol. Energieversorgung
Marie Skłodowska Curie • Raumfahrt
Verkehr
Stipends - MSC
Risikofinanzierung Klimaschutz, Ressourceneffizienz,
Rohstoffe
Research Infrastructure -
Allg. Gesellschaftsfragen
RIS Innovationen in KMU (integrativ, sicher, frei etc.)
www.consultech.de
Instruments+in+Horizon+2020+
1. Research collaborations
2. SME Funding
3. Access to risk financing
4. Co-Financing-Instruments (EC + Member states, .... )
www.consultech.deInstruments+Horizon+2020+–+FP7+(1)+
Horizon 2020 FP7
Integrated project (IP)
Research and
Innovation Action (RIA)
Focused project (STREP)
Integrated project (IP)
Innovation Action (IA)
Focused project (STIPs)
www.consultech.deMain+instruments+for+collabora@ve+
research+and+development+projects+
Research and Innovation Actions Innovation Actions
(RIA) (IA)
• Development of new knowledge • Plans, schemes, drafts for new,
• Feasibility tests modified or optimised products,
• Basic and applied research, processes or services
technology development and • Prototypes, demonstration and
integration pilot actions
• Prototypes (lab scale) • Transfer to market actions
• Small scale demonstration and • (large) product validation
pilot actions actions
100 % funding 70% funding
(100% funding for
non profit organisations)
One project – one funding rate www.consultech.deInstruments+Horizon+2020+–+FP7+(2)+
Horizon 2020 FP7
Support Action (SA)
Coordination and Support
Actions (CSA) Co-ordination Action (CA)
Network of Excellence
(NoE)
SME Instrument
-
www.consultech.deSME+Instrument+
• Phase 1: Feasibility study
3 phases • Phase 2: Development phase
• Phase 3: Marketing phase
• Phase 1: 4 cut-off dates p.a.
No deadlines • Phase 2: 1 cut-off date p.a. (“Health” more than one)
„bottom-up“
Pillars • 2 (Industrial Leadership) and 3 (Societal Challenges)
• Phase 1: lump sum
Funding rates • Phase 2: 70% (exception: 100% topic “Biomarker”)
• Phase 3: no funding
• Phase 1: 50.000 Euro per project
Funding • Phase 2: 1-2.5 mill. € (exception: 5 mill. € “Biomarker”)
• Phase 3: no funding
Coaching • Enterprise Europe Network (EEN)
www.consultech.deInstruments+Horizon+2020+–+FP7+(3)+
Horizon 2020 FP7
Programme co-funding ERA-NET, Art.185 activities
actions (AAL, EuroStars), JTIs (IMI)
Pre-Commercial
Procurement (PCP) -
Public Procurement of
Innovative Solutions (PPI) -
www.consultech.deInstruments+Horizon+2020+–+FP7+(4)+
Horizon 2020 FP7
Fast Track to Innovation -
Prizes -
- Research for SME
www.consultech.deFast+Track+to+Innova@on+
Accelerating Technology Transfer
• Time to grant = 6 months
Increasing participation of industry and SMEs
• Open for all types of organisations
Bottom-up calls from 2015
• 3 cut-off-dates p. a.
• Pillar 2: Industrial leadership
• Pillar 3: Societal challenges
Funding instrument
• Innovation action (70% funding rate, max. 5 partners, max. 3 mill. Euro funding)
Based on structure of national funding programmes
• „KMU-innovativ“
www.consultech.deInstruments+Horizon+2020+–+FP7+(5)+
Horizon 2020 FP7
Risk financing
(loans, equity) -
Public Private Public Private
Partnerships (PPP) Partnerships (PPP)
Public Public Public Public
Partnerships (P2P) Partnerships (P2P)
www.consultech.deRisk+financing+instruments+–+
New+in+Horizon+2020+
Loans Equities
venture capital
Loans for companies and for young, research-
innovative projects development and
Guarantees for creditors innovation intensive
companies
• Accompanying measures
• Implementation by European Investment Bank (EIB) /
European Investment Fund (EIF)
www.consultech.deAccompanying+measures+ Diffe
rent
rules
!
Public Private Partnerships (PPPs)
• Financed by Horizon 2020 + Industry
i.e. IMI2
• Financed by member states and EC
Public Public Partnerships (P2Ps)
(partly)
Source: KoWi www.consultech.dePreTdefined+instrument+for+each+call+
Participant Portal
Select a call
Topic description
Type of action
www.consultech.deSummary+
New+Instruments+in+Horizon+2020+
RIA • Research and Innovation Actions
IA • Innovation Actions
SME • SME Instrument
FTI • Fast track to innovation
Risk • Risk financing instruments
www.consultech.deBeteiligungs- und Förderregeln Dr. Daniel Schubart
Wer+kann+sich+beteiligen?+
Alle Personen und Rechtsformen
• Natürliche Personen und Personengesellschaften
• Juristische Personen
• Keine Firmen in Insolvenzverfahren
Prinzipiell Teilnehmer aus allen Ländern
• Ausnahmen
• ERA-NET, PPP, Bestimmungen im Call
www.consultech.deWer+wird+gefördert?+
Projektpartner
• EU Mitgliedsländern
• Mit dem Rahmenprogramm assoziierte Staaten
(Schweiz ?, Norwegen, Israel, Türkei, etc.)
• Best. Länder der 2. und 3. Welt
• Andere Teilnehmer eigene Finanzierung
• i.A. außereuropäische Länder der 1. Welt
• Ausnahme: spezielle Regelungen im Call
• China (Ausschreibungen in Landwirtschaft)
• USA (immer in „Gesundheit“)
www.consultech.deWie+wird+gefördert?+
Voraussetzung
• Projekt mit mind. 3 unabhängigen Partnern aus 3
Mitglieds- bzw. assoziierten Staaten
• Ausnahmen
• ERC, Mobilitätsprogramm, KMU Instrument,
CSA, im Arbeitsprogramm explizit festgelegt
• Erfolgreicher Evaluations- und Verhandlungsprozess
• Nachweis der Kosten durch Buchführung
• Führen von Time-Sheets
• Ausnahme: 100% Tätigkeit im Projekt
• s. part A general annexes, General Work Programme
www.consultech.deWie+wird+gefördert?+
Indirekte
Erstattungsfähige Nicht
Kosten /
Kosten erstattungsfähig
Overhead
Personalkosten
Pauschale von 25% auf
Sachkosten Zölle, direkte, erstattungsfähige
Kosten
Wechselkurzverluste,
Reisekosten
Schulden,
Unteraufträge
Kosten anderer Projekte,
! Keine
Projektspezifische Kosten unverhältnismäßige Kosten Vollkostenabrechnung !
(eventuell für non-profit
Forschungsorganisationen)
MwSt. (Partnerabhängig)
• Financial guide -> annotated model grant agreement
www.consultech.deFunding+rates+for+eligible+costs+
Funding rate*
100 % 70 %
Research and Coordination
Innovation
innovation and Support
Actions (IA)**
actions (RIA) Actions (CSA)
* direct and indirect costs
** except Universities, public institutions (100% funding)
www.consultech.deZusammenfassung+
Transnationale Verbundforschung
• Ausnahmen: MSC, SME-Instr., call spezifisch
i.A. Industriebeteiligung wichtig, aber ausschreibungsabhängig
Time to Grant
• Maximal 8 Monate ab Call – Deadline
Eine Förderquote pro Projekt
• 100% oder 70% auf direkte Kosten + Overhead
• Max. ein Certificate on Financial Statements pro Partner
• Weniger Audits
Partner aus den USA in Health-Pillar förderbar
Klinische Studien förderbar (s. Ausschreibung)
www.consultech.deRechtliche Aspekte Dr. Daniel Schubart
Important+Agreements+
www.consultech.deModel+Grant+Agreement+(MGA)+
A single document with all provisions
no more Core agreement + Annex II, specific Annex III or special
clauses
Electronic signature of
Grant Agreement Accession Forms
coordinator and European by all beneficiaries
Commission (Annex 3)
www.consultech.deModel+Grant+Agreement:+Structure+
Chapter 1: General
Annex I: Description of the
action
Chapter 2: Action
Annex II: Estimated budget
Chapter 3: Grant
Annex III: Accession Form for
Chapter 4: Rights and obligations Beneficiaries
Annex IV: Model for Financial
Chapter 5: Division of roles statements
Chapter 6: Rejection, reduction, Annex V: Model of Certificate on
penalties, termination, etc the financial statements
Annex VI: Model of Certificate on
Chapter 7: Final provisions the methodology
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
• Art 1: subject of the agreement
Chapter 2: Action
Chapter 3: Grant
Chapter 4: Rights and obligations
Chapter 5: Division of roles
Chapter 6: Rejection, reduction, penalties, termination, etc
Chapter 7: Final provisions
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
Chapter 2: Action
• Art 2-4 Action, duration and budget
Chapter 3: Grant
Chapter 4: Rights and obligations
Chapter 5: Division of roles
Chapter 6: Rejection, reduction, penalties, termination, etc
Chapter 7: Final provisions
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
Chapter 2: Action
Chapter 3: Grant
• Art 5-6 Amount, reimbursement rates, eligible costs
Chapter 4: Rights and obligations
Chapter 5: Division of roles
Chapter 6: Rejection, reduction, penalties, termination, etc
Chapter 7: Final provisions
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
Chapter 2: Action
Chapter 3: Grant
Chapter 4: Rights and obligations
• Art 7–16: To implement the action: resources, in-kind
contributions, subcontracts
• Art 18-22: Grant administration: reporting, payments, audits
• Art 23-31: Background and results: access rights, protection of
results, exploitation, dissemination
• Art 32-40: Others: gender equality, ethics, confidentiality
Chapter 5: Division of roles
Chapter 6: Rejection, reduction, penalties, termination, etc
Chapter 7: Final provisions
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
Chapter 2: Action
Chapter 3: Grant
Chapter 4: Rights and obligations
Chapter 5: Division of roles
• Art 41: Roles and responsibilities, internal arrangements
Chapter 6: Rejection, reduction, penalties, termination, etc
Chapter 7: Final provisions
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
Chapter 2: Action
Chapter 3: Grant
Chapter 4: Rights and obligations
Chapter 5: Division of roles
Chapter 6: Rejection, reduction, penalties, termination, etc
• Art 42-45: Rejection, reduction, recovery and penalties
• Art 46-51: Liability, Suspension and termination of the action
Chapter 7: Final provisions
www.consultech.deModel+Grant+Agreement+
Chapter 1: General
Chapter 2: Action
Chapter 3: Grant
Chapter 4: Rights and obligations
Chapter 5: Division of roles
Chapter 6: Rejection, reduction, penalties, termination, etc
Chapter 7: Final provisions
• Art 52-58: Accession, entry into force, amendments, applicable
law
www.consultech.deAnnotated+Model+Grant+Agreement+
! Detailed+explana@on+of+Art.+1+T+6++
! Interpreta@on,+defini@ons,+examples+
! Similar+to+financial+guide+in+FP7+
! h:p://ec.europa.eu/research/par@cipants/data/ref/h2020/
grants_manual/amga/h2020Tamga_en.pdf+
+
www.consultech.deConsor7um(Agreement+
• Consortium Agreement (MGA Art. 41.3)
• Is mandatory unless otherwise stated
• There will be a template like the DESCA template
www.consultech.deConsor7um(Agreement+
• internal organisation
• distribution of EU funding
• additional matters regarding Foreground and Background
CA • settlement of internal disputes, breaches, sanctions
should deal • confidentiality
with • liability and indemnification
• receipts
• grant reduction
• etc.
www.consultech.deElectronic(communica7on((
+
Electronic signature
• Of the Grant Agreement coordinator and European Commission
• Of the Accession Forms by all beneficiaries
• Of the Amendments
• Financial Statements and Technical reports
• LEAR - important: assigns roles in IT system for GA signature and
management
Communication between the Commission and the
beneficiaries
• Through the Participant Portal
• Electronic-only submission of reports
www.consultech.deWie gestaltet sich der Antragsprozess? Dipl. Ing. Ursula Wirtz
Administra@ve+Aspects++
Documents & Definitions
Application: process & levels
Participant Portal
Registration process – organisation related
Registration process – project related
www.consultech.deImportant+documents+T+overview+
Specific Programme Horizon 2020
Rules for participation
work programme – call topics & general annexes
Guide for evaluators
Model Grant Agreement
Annotated Model Grant Agreement
www.consultech.deDefini@ons+
Participant Portal • single-entry point for interactions between participants and EC
Beneficiary • legal entity which benefit from the GA
Coordinator • contact point of the consortium towards EC
MGA / CA • Model Grant Agreement / Consortium Agreement
• European Commission Authentification Service
ECAS to create an account for the portal based on your email address
• Participant Identification Code (PIC) ,
PIC unique identifier for every validated organisation
• Rights a user can have in in projects and/or organisations
Roles (e.g. Participant contact, LEAR, LSign, FSign)
• Legal Entity Appointed Representative, correspondent on all legal
LEAR status related issues
www.consultech.deApplica@on:+Process+&+Levels+
Administrative Part Scientific Part
Organisation Level Proposal Level
project idea
ECAS Account register for a call
Call text
PIC - Registration download template
Part B consortium
Verification complete Form A project plan
Partner /financials
Financial & Legal Viability work packages
Check upload Part B
financials
Lear-Appointment Submission
Part B writing
www.consultech.deAdministra@ve+Part:++
Registra@on+Process+–+Two+Levels+
1. ECAS Account 6. Register for a call
2. PIC - Registration 7. Download template
Part B
3. Verification 8. Complete Form A
Partner /financials
4. Financial & Legal
Viability Check 9. Upload Part B
5. LEAR-Appointment 10. Submission
www.consultech.deThe+Par@cipant+Portal+
A(single(gateway(for((
" informa@on+++
(documents,+calls)+
" registra@on++
" proposal++applica@on++
" project+management+
(
https://ec.europa.eu/research/participants/portal/desktop/en/home.html
www.consultech.dePar@cipant+Portal+w/o+Login+
Funding How to My AREA Experts Support
opportunities participate • ….. • FAQ for • FAQ
• H2020 • Documents • ….. Experts
• Calls • Beneficiary • ….. • Funded
• FP7 Register • ….. Projects
• Financial
• Calls
Viability
Self-Check
www.consultech.dePar@cipant+Portal+with+Login+
Funding How to My AREA Experts Support
opportunities participate • Organisation
• H2020 • Documents related area • FAQ for • FAQ
• Calls • Proposal(s) Experts
• Funded
• FP7 for funding Projects
• Calls • Financial • Project(s) • Expert
Viability Self- related service registration
Check • Managing roles
www.consultech.deExample:+My+Proposals+
www.consultech.deExample:+My+Projects+
www.consultech.deRegistra@on+Process+–+Two+Levels+
1. ECAS Account 6. Register for a call
2. PIC - Registration 7. Download template
Part B
3. Verification 8. Complete Form A
Partner /financials
4. Financial & Legal
Viability Check 9. Upload Part B
5. LEAR-Appointment 10. Submission
www.consultech.de1. Create+Your+Personal+ECAS+
Account+
The+unique(iden7fier((
for(a(physical(person++
is+the+eTmail+address+
choose “Register”
create an ECAS account
receive identification email
finalize user registration
Login
www.consultech.de2.++Get+Organisa@on’s+PIC+
choose PIC number
Fill in the
“Beneficiary Submit on screen
forms
Register” and by email
www.consultech.de3.+ +Verifica@on+of+Organisa@on’s+Legal+
Existence+and+Status+
Public Entities
• Legal Entity Form (public status)
• official document establishing your organisation
• VAT registration document or document attesting VAT exemption
Non profit research organisations
• Legal Entity Form (public status)
• document mentions
• status of a non-profit organisation by national or international law
• that your organisation carries out research or technological
development as one of its main objectives
Source: Rules of verification; not yet available for H2020
www.consultech.de3.++Verifica@on+of+Organisa@on’s+Legal+
Existence+and+Status+
Private Entities
• Legal Entity Form (private status)
• extract of registration (Company Register, Official Journal)
• registration number
• VAT registration document (official document not older than 6 months ago)
Small and Medium Sized Enterprises
(additional)
• SME check-list
• Annual Balance sheet for the last approved accounting period
• Profit and Loss account for the last approved accounting period
• Appendix indicating the number of declared employees
and possible ownership for the last approved accounting period.
www.consultech.deSMETDefini@on+
Recommendation 2003/361/EC relating to the definition of micro,
small and medium-sized enterprises
Enterprises (incl. linked organisations), which
have an annual
have an annual
balance sheet
employ less than turnover not
total not
250 persons exceeding
exceeding
50 million euro
43 million euro
http://ec.europa.eu/enterprise/policies/sme/files/sme_definition/sme_user_guide_de.pdf
www.consultech.de+5.+Appoint+a+LEAR++
+++
Legal signatory (e.g. managing director / chancellor)
• appoint the LEAR
• sole formal process using blue ink signature
European Commission
• send password
• send Link
LEAR
• use validation link
• finalise process via password
• Nominate+ • nominate+ • onlineT
LSIGN FSIGN update+of+
organisa@on+
data
www.consultech.deRegistra@on+Process+–+Two+Levels+
1. ECAS Account 6. Register for a call
2. PIC - Registration 7. Download template
Part B
3. Verification 8. Complete Form A
Partner /financials
4. Financial & Legal
Viability Check 9. Upload Part B
5. LEAR-Appointment 10. Submission
www.consultech.de6.1.+Call+Registra@on+
! find+your+topic+
+
! use+sec@on++
“submission++
service”++
to+register++
for+a+proposal+
www.consultech.de6.2.+Call+Registra@on+
! PIC+is+required+
www.consultech.de7.+Download+Part+B+(S&T)+
Download+Templates+to+drap+Part+B+
www.consultech.de8.+Add+Partners+
www.consultech.de8. Completion of Part A
! Details
! Name, address of
organisation
! Dept. carrying out
work
! Responsible scientist
! Budget (stage 1 vs.
stage 2)
! Ethics issues
! Call specific
questionsInhaltliche Aspekte der Antragstellung Dr. Daniel Schubart
Birds+Eye+Perspec@ve+–+From+Idea+to+
Proposal+Submission+
• One or two • Research
stage proposal organisations
• Companies
• others
Find and
interpret Assemble
appropriate consortium
Call
Administrative
Write proposal
aspects
• Scientific part • Coordinator
• Financials • Partner
• PIC, LEAR etc
www.consultech.deFind a call ! Participant portal / calls ! Search & filter function ! Pillar level ! In general, call texts broader than FP7 ! ConsulTech Homepage Horizon 2020 ! Headlines ! Link to PP page
Example:+Advancing+bioinforma@cs+to+
meet+biomedical+and+clinical+needs+
www.consultech.deParticipant Portal
! Important documents ! Call specific information
! Political background papers ! List of countries and applicable
(framework programme, model rules for funding
grant agreement) ! Eligibility and admissibility
! Work programme conditions
! General annexes ! Evaluation criteria and
! call topics procedure, scoring and threshold
! Rules for participation ! Guide to the submission and
evaluation process
! Financial guide
! Proposal templateTopics+2014+–+Health+/+Examples+
Area Topic Instrument Budget
Improving diagnosis PHC 10: Development of new diagnostic tools RIA (100%) 48 Mio. €
and technologies: in vitro devices, assays and
platforms (4-6 Mio. €)
PHC 12: Clinical validation of biomarkers RIA (100%) ca. 60 Mio. €
and/or diagnostic medical devices
(50.000 € for Phase 1, 1-5 Mio. € in Phase 2)
Innovative PHC 13: New therapies for chronic non- RIA (100%) 60 Mio. €
treatments and communicable diseases (4-6 Mio. €)
technologies
PHC 15: Clinical research on regenerative RIA (100%) 72 Mio. €
medicine (4-6 Mio. €)
PHC 17: Comparing the effectiveness of RIA (100%) 48 Mio. €
existing healthcare interventions in the
elderly (4-6 Mio. €)
To be found in work programme
www.consultech.deBasics+of+a+good+proposal+
• Scientific, technical excellence
• Reference to political objectives
• Reference to call and work programme
good
idea
Excellent
consortium
perfect • Meet formal requirements
formulated • Please reviewers
proposal
www.consultech.deProposal template & evaluation
! Review process
! Score of each chapter from 1
(worst) – 5 (best)
! Threshold: call specific
! Page limits
! Max. 7 / 10/ 15 pages for
stage 1 (call specific)
! Max. 70 pages for stage 2
! Financial planning / BudgetProposal+Template+
! 1.+Excellence+ ! Work+plan+
! Objec@ves+ ! Management+structure+&+
! Rela@on+to+work+programme+ procedures+
! Concept+&+approach+ ! Consor@um+as+a+whole+
! Ambi@on+ ! Resources+
! 2.+Impact+ ! 4.+Members+of+consor@um+
! Expected+impact+ ! 5.+Ethics+&+Security+
! Measures+to+maximise+impact+
! 3.+Implementa@on+
www.consultech.deImportant+aspects+for+proposal+
wri@ng+
Topic
• Analyse conditions of application (formal, impact)
Analyse the call
• Is this an appropriate topic?
• Is my idea fitting the topic text?
• Does my idea meet the goals of the call?
Understand evaluation criteria
• Annex H, reviewer’s guide
• Write comprehensible
www.consultech.deConsor@um+
+ +Iden@fy+project+partners+++
• Minimum+of+partners+ • Type+of+beneficiary+
• SME+par@cipa@on+ • Field+of+ac@vi@es++
• Complementary+characteris@cs+ • Interdisciplinary+
www.consultech.deOverview+
Applica@on+process+–+step+by+step+
+ Submit++
just+in++
update++ @me+
2 upload++
Part+B+to+
financials+in+
Part+A+
according+to+
write++ Par@cipant+ Part+B+
Part+B++ Portal+
Download+
template+for+
complete++ Part+B+
Form+A+ add+Partners+
(partner+and+ to+Form+A+
project+ register+for+ (Portal)+
specific)++ call+/+topic++
make+a+Lear+T+ (coordinator)+
appointment+
finish+Financial+
1 Registra@on+of+
&+Legal+
Viability+Check++
register+your+
create+ECAS+ organisa@on+
Account+at+ (PIC)+
par@cipant+
portal+ www.consultech.deVorstellung aktueller relevanter Aufrufe Dr. Daniel Schubart
Important+calls+
Call identifier: H2020-PHC-2014-two-stage
• Pillar or sub-theme: e.g. PHC, SFS, LEIT, NMP, SMEINST, ICT
• Deadline: e.g. 2014
Work programme (budget: pro call PHC und topic PHC-12)
Examples
• New therapies for chronic non-communicable diseases
• Development of new diagnostic tools and technologies: in vitro devices, assays
and platforms
• Vaccine development for poverty-related and neglected infectious diseases:
tuberculosis
• Advancing bioinformatics to meet biomedical and clinical needs
www.consultech.deTopics+2014+–+Health+/+Examples+
Area Topic Instrument Budget
Understanding PHC 1: Understanding health, ageing and RIA (100%) 54 Mio. €
health, ageing and disease: determinants, risk factors and
disease pathways (4-6 Mio. €)
Effective health PHC 5: Health promotion and disease RIA (100%) 24 Mio. €
promotion, disease prevention: translating “-omics” into
prevention, stratified approaches (4-6 Mio. €)
preparedness and
screening
PHC 6: Evaluating existing screening and RIA (100%) 15 Mio. €
prevention programmes (2-3 Mio. €)
PHC 7: Improving the control of infectious RIA (100%) 20 Mio. €
epidemics and foodborne outbreaks through
rapid identification of pathogens (15-20 Mio.
€)
PHC 8: Vaccine development for poverty- RIA (100%) 25 Mio. €
related and neglected infectious diseases:
Tuberculosis (15-20 Mio. €)
www.consultech.deTopics+2014+–+Health+/+Examples+
Area Topic Instrument Budget
Improving diagnosis PHC 10: Development of new diagnostic tools RIA (100%) 48 Mio. €
and technologies: in vitro devices, assays and
platforms (4-6 Mio. €)
PHC 12: Clinical validation of biomarkers RIA (100%) ca. 60 Mio. €
and/or diagnostic medical devices
(50.000 € für Phase 1, 1-5 Mio. € in Phase 2)
Innovative PHC 13: New therapies for chronic non- RIA (100%) 60 Mio. €
treatments and communicable diseases (4-6 Mio. €)
technologies
PHC 15: Clinical research on regenerative RIA (100%) 72 Mio. €
medicine (4-6 Mio. €)
PHC 17: Comparing the effectiveness of RIA (100%) 48 Mio. €
existing healthcare interventions in the
elderly (4-6 Mio. €)
To be found in Work programme
www.consultech.deExample+1:+New+therapies+for+chronic+
nonTcommunicable+diseases+
www.consultech.deExample+1:+New+therapies+for+chronic+
nonTcommunicable+diseases+
! Specific+challenge:+Chronic+nonTcommunicable+diseases+represent+a+significant+burden+on+individuals+and+healthcare+
systems.+Innova@ve,+cost+effec@ve+therapeu@c+approaches+are+required+to+provide+the+best+quality+of+care+when+
preven@on+fails.+While+a+considerable+amount+of+knowledge+has+been+generated+by+biomedical+research+in+recent+
years,+the+development+of+new+therapies+is+stagna@ng,+in+part+due+to+a+lack+of+clinical+valida@on.+
! Scope:+Clinical+trial(s)+suppor@ng+proof+of+concept+in+humans+to+assess+the+poten@al+clinical+efficacy+of+the+novel+
therapeu@c+concept(s)+and+/+or+op@misa@on+of+available+therapies+(e.g.+drug+repurposing).+The+applica@on+may+build+
on+preTexis@ng+preTclinical+research+and+addi@onal+results+from+large+scale+databases.+A+concise+feasibility+assessment+
jus@fied+by+available+published+and+preliminary+results+and+suppor@ng+data+should+also+be+provided.+Considera@ons+of+
effec@veness+and+poten@al+clinical+benefit+(possibly+including+real+world+data)+should+be+integrated+in+the+applica@on+
if+relevant.+++++++++
The+Commission+considers+that+proposals+reques@ng+a+contribu@on+from+the+EU+of+between+EUR+4+and+6+million+
would+allow+this+specific+challenge+to+be+addressed+appropriately.+Nonetheless,+this+does+not+preclude+submission+and+
selec@on+of+proposals+reques@ng+other+amounts.+
! Expected+impact:+New+therapeu@c+strategies,+adapted+where+relevant+to+the+differing+needs+of+men+and+women,+with+
the+highest+poten@al+to+generate+advances+in+clinical+prac@ce+for+chronic+diseases,+including+mul@T+or+comorbidity,+
ready+for+further+development.+
Early+exclusion+of+candidate+strategies+unlikely+to+succeed.+
Contribute+to+the+improvement+of+the+therapeu@c+outcome+of+major+chronic+health+issues+with+significant+impact+on+
burden+of+diseases+both+for+individual+pa@ents+and+for+health+care+systems.+
! Type+of+ac@on:+Research+and+innova@on+ac@ons+
www.consultech.deExample+2:+Clinical+valida@on+of+
biomarkers+and/or+diagnos@c+medical+
devices+(PHCT12T2014T1)+
! SME+instruments+(100%+funding+!)+
! Specific+challenge:++
! Biomarkers+are+used+in+clinical+prac@ce+to+describe+both+normal+and+
pathological+condi@ons.+They+can+also+have+a+prognos@c+or+a+predic@ve+
power.+They+are+therefore+increasingly+used+in+medicine+and+many+
poten@al+biomarkers+are+proposed+every+year.+
! Only+a+few+of+them+are+however+validated+for+use+in+a+clinical+research+
sevng.+Such+valida@on+implies+the+demonstra@on+of+a+link+to+a+per@nent+
clinical+endpoint+or+process,+as+well+as+a+robust+and+appropriate+analy@cal+
method.+
! The+clinical+valida@on+of+biomarkers+will+be+increasingly+important+for+the+
development+of+new+diagnos@cs,+and+this+is+a+research+area+where+many+
small+European+companies+are+ac@ve.+
! Improved+clinical+decisions+should+lead+to+be:er+health+outcomes+while+
contribu@ng+to+the+sustainability+of+the+health+care+system.+ www.consultech.deExample+2:+Clinical+valida@on+of+
biomarkers+and/or+diagnos@c+medical+
devices+(PHCT12T2014T1)+
! Scope:++
! The+SME+instrument+consists+of+three+separate+phases+and+a+coaching+and+
mentoring+service+for+beneficiaries.+Par@cipants+may+apply+to+phase+1+with+a+
view+to+applying+to+phase+2+at+a+later+date,+or+directly+to+phase+2.+
! Proposals+submi:ed+to+phase+1+shall+consist+of+a+drap+business+plan+and+
feasibility+study+verifying+the+technological/prac@cal+and+economic+viability+
of+the+clinical+valida@on+proposed.+These+may,+for+example,+comprise+risk+
assessment,+market+study,+user+involvement,+intellectual+property+(IP)+
management,+innova@on+strategy+development,+partner+search,+feasibility+
of+concept+etc.+Proposals+may+analyse+bo:lenecks+preven@ng+advance+of+
the+applicant+SME+in+this+area+and+iden@fy+how+a+phase+2+proposal+may+
contribute+to+a:aining+growth+or+sustainability.+
! The+main+outcome+of+the+proposal+should+be+a+detailed+business+plan.+
Funding+for+phase+1+will+be+provided+in+the+form+of+a+lump+sum+of+EUR+
50.000+and+proposals+should+have+a+dura@on+of+around+6+months.+
www.consultech.deExample+2:+Clinical+valida@on+of+
biomarkers+and/or+diagnos@c+medical+
devices+(PHCT12T2014T1)+
! In+phase+2+proposals+should+address+the+specific+challenge+described,+elaborated+in+the+scope+sec@on+
above,+and+demonstrate+high+poten@al+in+terms+of+applicant's+compe@@veness+and+growth+
underpinned+by+a+strategic+business+plan.+
! Proposals+shall+be+based+on+a+business+plan+developed+either+through+phase+1+or+another+means.+
Par@cular+a:en@on+must+be+paid+to+IP+protec@on+and+ownership;+applicants+should+provide+evidence+
of+the+possibility+of+commercial+exploita@on+(‘freedom+to+operate’).+
! The+clinical+valida@on+of+exis@ng+poten@al+biomarkers+(not+the+iden@fica@on+of+new+ones)+is+sought.+
This+valida@on+should+provide+evidence+for:+high+analy@cal+validity;+appropriate+sensi@vity+and+
specificity;+clinical+validity/+u@lity.+Preference+will+be+given+to+valida@on+of+biomarkers+with+high+
poten@al+for+short+term+uptake+into+clinical+prac@ce.+
! In+addi@on,+valida@on+of+the+clinical+performance+of+new+diagnos@c+devices+can+be+supported,+either+in+
combina@on+with+the+biomarker+valida@on,+or+against+exis@ng+standards.+
! Both+in+vivo+and+in+vitro+poten@al+biomarkers+are+eligible.+Preference+will+be+given+to+the+valida@on+of+
disease+related+biomarkers+(i.e.+diagnos@c,+suscep@bility/risk,+monitoring+and+prognos@c+biomarkers)+
! Proposals+shall+contain+a+specifica@on+for+the+outcome+of+the+project,+including+a+first+
commercialisa@on+plan,+and+criteria+for+success.+
! The+Commission+considers+that+phase+2+proposals+reques@ng+a+contribu@on+from+the+EU+of+between+
EUR+1+and+5+million+would+allow+this+specific+challenge+to+be+addressed+appropriately.+Nonetheless,+
this+does+not+preclude+submission+and+selec@on+of+proposals+reques@ng+other+amounts.+Phase+two+
projects+should+duly+jus@fy+their+dura@on+making+reference+to+obtaining+pa@ent+samples,+ensuring+
pa@ent+follow+up,+etc.+
www.consultech.deExample+2:+Clinical+valida@on+of+
biomarkers+and/or+diagnos@c+medical+
devices+(PHCT12T2014T1)+
! Expected+impact+
! Increased+clinical+availability+and+exploita@on+of+biomarkers+for+the+benefit+of+
the+pa@ent.+
! New+diagnos@c+devices.+
! Facilita@on+of+entry+of+improved+diagnos@cs+in+the+clinic+and+the+market.+
! Support+for+the+implementa@on+of+the+Commission+proposal+for+a+revised+in+
vitro+diagnos@c+devices+regula@on[1].+
! Enhancing+profitability+and+growth+performance+of+SMEs+by+combining+and+
transferring+new+and+exis@ng+knowledge+into+innova@ve,+disrup@ve+and+
compe@@ve+solu@ons+seizing+European+and+global+business+opportuni@es.+
! Contribu@on+to+the+sustainability+of+health+care+systems.+
! Increased+likelihood+of+market+uptake+and+distribu@on+of+resul@ng+
innova@ons+tackling+the+abovemen@oned+specific+challenge(s)+in+a+sustainable+
way.+
! Leveraging+of+private+investment+in+clinical+valida@on+as+described+above,+
notably+leverage+of+private+coTinvestor+and/or+followTup+investments.+
www.consultech.deSummary+
! Simplifica@on+?+ ! One+or+two+stage+proposals+
! Rules+of+par@cipa@on+and+ ! Refer%to%topic%text%and%
funding+(finances,+@meT evalua2on%criteria%
recording,+single+indirect+cost+ ! Quality%of%consor2um%%
rate,+only+2+funding+rates,+less+ ! Innova2on%of%idea%%
CFS,+less+audits)+
! Find+calls!?+ ! Legal+aspects+
! Electronic+submission+(grants,+ ! GA,+CA,+IP+rules+
amendments)+ ! Amendments+
! Quicker+@me+to+grant+ ! Budget+alloca@on+flexible+
! Applica@on+process++ ! Consor@um+members+may+be+
! Administra@ve,+financial+&+ exchanged+
technical+part+
www.consultech.deWebsites+
! Research+par@cipant+portal:++
h:p://ec.europa.eu/research/par@cipants/portal/desktop/en/
opportuni@es/index.html+
! NKS+Deutschland+&+BMBF:+Informa@on+&+Ansprechpartner:+
www.horizont2020.de+
! h:p://www.consultechTct.de/H2020/+
www.consultech.deThank you very much
for your attention!
Dr. Daniel Schubart
Dipl.-Ing. Heidrun Gürtler
Dipl.-Ing. Ursula Wirtz
Tel.: +49 30 7720 5920
Email: info@consultech.de
www.consultech.deYou can also read
